Ocular pharmacology of topotecan and its activity in retinoblastoma

Retina

Volumn 34, Issue 9, 2014, Pages 1719-1727

  Schaiquevich, Paula ^a   Carcaboso, Angel M ^b   Buitrago, Emiliano ^c   Taich, Paula ^a   Opezzo, Javier ^c   Bramuglia, Guillermo ^c   Chantada, Guillermo L ^a,b  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Camptothecins; Ocular pharmacokinetics; Retinoblastoma; Topotecan; Vitreous

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; MELPHALAN; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER CELL LINE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG POTENTIATION; DRUG TOLERABILITY; EYE DISEASE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PORCINE MODEL; RETINOBLASTOMA; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC CIRCULATION; VITREOUS BODY; ANIMAL; DRUG ADMINISTRATION ROUTE; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; RETINAL NEOPLASMS; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION ROUTES; HUMANS; INTRAVITREAL INJECTIONS; RETINAL NEOPLASMS; RETINOBLASTOMA; TISSUE DISTRIBUTION; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TUMOR CELLS, CULTURED; VITREOUS BODY;

EID: 84906937368     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000253     Document Type: Review

References (61)

1. Canturk S, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol 2010;94:1432-1436.
2. Kingston JE, et al. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996;114:1339-1343.
3. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol 2010;21:203-212.
4. Shields CL, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology 2009;116:544-551 e1.
5. Lee SH, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplant 2008;42:385-391.
6. Gaudana R, et al. Recent perspectives in ocular drug delivery. Pharm Res 2009;26:1197-1216.
7. Doz F, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1995;13:902-909.
8. Chantada GL, et al. Phase II window of idarubicin in children with extraocular retinoblastoma. J Clin Oncol 1999;17:1847-1850.
9. Parareda A, et al. Intra-arterial chemotherapy for retinoblastoma. Challenges of a Prospective Study. Acta Ophthalmol 2013. In press.
10. Schouten-van Meeteren AY, et al. Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay. Cancer 2001; 92: 2933-2940.
11. Barrie SE, et al. High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells. Anal Biochem 2003;320:66-74.
12. Hendig D, et al. Characterization of the ATP-binding cassette transporter gene expression profile in Y79: a retinoblastoma cell line. Mol Cell Biochem 2009;328:85-92.
13. Suarez F, et al. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma. Invest Ophthalmol Vis Sci 2007;48:3437-3440.
14. Pina Y, et al. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Invest Ophthalmol Vis Sci 2012;53:996-1002.
15. Dyer MA, Rodriguez-Galindo C, Wilson MW. Use of preclinical models to improve treatment of retinoblastoma. PLos Med 2005;2:e332.
16. Shields CL, et al. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120:460-464.
17. Shen J, et al. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res 2009;69:5885-5892.
18. Blaney SM, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003;21:143-147.
19. Dimaras H, et al. Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation. Ophthalmic Genet 2009;30:121-126.
20. Nitschke R, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II Study. J Pediatr Hematol Oncol 1998;20:315-318.
21. Frangoul H, et al. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin Cancer Res 1999;5:3956-3962.
22. Chantada GL, et al. Activity of topotecan in retinoblastoma. Ophthalmic Genet 2004;25:37-43.
23. Laurie NA, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 2005; 11:7569-7578.
24. Athale UH, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 2002;20:88-95.
25. Nemeth KM, et al. Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer 2011;117:421-434.
26. Qaddoumi I, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 2012;118:5663-5670.
27. Panetta JC, et al. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 2008;14:318-325.
28. Santana VM, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003;9:633-640.
29. Schaiquevich P, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer 2013;60:766-770.
30. Francis JH, et al. Carboplatin +/-topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One 2013; 8:e72441.
31. Gobin YP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 2011;129:732-737.
32. Schaiquevich P, et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci 2012;53:4205-4212.
33. Brennan RC, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res 2011;71: 4205-4213.
34. Pescosolido N, et al. Topotecan hydrochloride effects on retinal vessels in newborn rats. Histol Histopathol 2012;27:497-506.
35. Han S, Wei W. Camptothecin induces apoptosis of human retinoblastoma cells via activation of FOXO1. Curr Eye Res 2011;36:71-77.
36. Giuliano M, et al. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci 1998;39:1300-1311.
37. Barot M, et al. In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management. Exp Eye Res 2014;118:61-71.
38. Dunkel IJ, et al. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer 2010;55:55-59.
39. Wilson TW, et al. Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol 1996;114:1390-1395.
40. Abramson DH. Periocular chemotherapy for retinoblastoma: success with problems Arch Ophthalmol 2005;123:128-129; author reply 129.
41. Mendelsohn ME, et al. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 1998;116:1209-1212.
42. Carcaboso AM, et al. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci 2007;48:3761-3767.
43. Chantada GL, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci 2009;50:1492-1496.
44. Pontes de Carvalho RA, et al. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci 2006;47:4532-4539.
45. Carcaboso AM, et al. Episcleral implants for topotecan delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 2010;51:2126-2134.
46. Tsui JY, et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 2008;49:490-496.
47. Van Quill KR, et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 2005;112:1151-1158.
48. Spotnitz WD. Fibrin sealant: past, present, and future: a brief review. World J Surg 2010;34:632-634.
49. Mallipatna AC, et al. Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol 2011;129:738-745.
50. Yousef YA, et al. No ocular motility complications after subtenon topotecan with fibrin sealant for retinoblastoma. Can J Ophthalmol 2013;48:524-528.
51. Munier FL, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 2012;96:1078-1083.
52. Edelhauser HF, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci 2010;51:5403-5420.
53. Buitrago E, et al. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment. Exp Eye Res 2010;91:9-14.
54. Darsova D, et al. Topotecan vitreous and plasma levels and retinal toxicity after transcorneal intravitreal delivery in healthy albino rabbits: alternative retinoblastoma treatment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156:318-323.
55. Buitrago E, et al. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Exp Eye Res 2013;108:103-109.
56. Souza LG, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm 2011;79:189-196.
57. Gary-Bobo M, et al. Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: drug delivery, one and two-photon photodynamic therapy. Int J Pharm 2012;432:99-104.
58. Schaiquevich P, et al. Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. Retina 2012;32: 387-395.
59. Francis JH, et al. Electroretinogram monitoring of dosedependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review. PLoS One 2014;9: e84247.
60. Tse BC, et al. Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings. JAMA Ophthalmol 2013;131:903-911.
61. Taich P, et al. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology 2013. In press.